Tumor Registry Pancreatic Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

2325 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-12-31

Study Completion Date

2024-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The registry aims to collect and analyse information on the antineoplastic treatment of patients with unresectable locally advanced or metastatic pancreatic cancer, treated in palliative intention (cohort 1) and patients with localized, resectable pancreatic cancer treated in neo-adjuvant or adjuvant intention (cohort 2) in daily routine practice in Germany. The registry will follow up patients for two years. It will identify common sequences of treatments used as well as changes in the treatment of the disease. Health-related quality of life will be analysed during the course of the treatment (PanLife). Based on the available data a prognostic score will be developed.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Neoadjuvant Treatment in Resectable Pancreatic Cancer

NCT01900327

Pancreatic Cancer

TERMINATED PHASE3

Randomized Multicenter Phase II/III Study With Adjuvant Gemcitabine Versus Neoadjuvant / Adjuvant FOLFIRINOX for Resectable Pancreas Carcinoma

NCT02172976

Resectable Prancreas Carcinoma

COMPLETED PHASE2/PHASE3

Survival, Quality of Life and Resectability in Locally Advanced Pancreatic Cancer

NCT05356039

Pancreas Cancer Pancreas Neoplasm Pancreas Disease +6 more

RECRUITING

Patient Reported Outcomes Registry in Patient With Cancer Cachexia

NCT02983500

Metastatic Pancreatic Cancer NSCLC, Metastatic

COMPLETED

Austrian Registry for Evaluation of Treatment Patterns and Outcome in Patients With Advanced Pancreatic Ductal Adenocarcinoma (PDAC)

NCT05526443

Pancreatic Cancer Advanced Pancreatic Carcinoma

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pancreas Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort 1

2,200 patients with unresectable locally advanced or metastatic pancreatic cancer, treated in palliative intention

No interventions assigned to this group

Cohort 2

125 patients with localized, resectable pancreatic cancer treated in neo-adjuvant or adjuvant intention

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* resectable or locally advanced/metastatic pancreatic cancer
* 18 years and older
* Antineoplastic treatment
* Date of consent no later than 2 weeks after start of first-line treatment

Exclusion Criteria

* No pancreatic cancer
* Below 18 years and older
* No antineoplastic treatment
* Date of consent later than 2 weeks after start of first-line treatment

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No